RMR Wealth Builders Makes New $1.36 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RMR Wealth Builders acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,141 shares of the biopharmaceutical company’s stock, valued at approximately $1,358,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Manchester Capital Management LLC grew its position in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 18 shares in the last quarter. Adirondack Trust Co. boosted its stake in Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 18 shares during the last quarter. Finally, Financial Perspectives Inc boosted its stake in Regeneron Pharmaceuticals by 10.9% in the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 19 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on REGN shares. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, June 2nd. UBS Group dropped their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research note on Thursday, June 5th. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $700.00 to $580.00 in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $836.48.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $521.84 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $56.34 billion, a PE ratio of 13.63, a P/E/G ratio of 2.34 and a beta of 0.31. The company’s 50 day simple moving average is $563.74 and its two-hundred day simple moving average is $651.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.